查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971161

阿茲海默症市場分析及預測（至2035年）：按類型、產品類型、服務、技術、應用、最終用戶、設備、採用類型和階段分類

Alzheimers Disease Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 356 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

阿茲海默症市場預計將從2024年的30億美元成長到2034年的234億美元，複合年成長率約為23%。阿茲海默症市場涵蓋用於治療和潛在治療阿茲海默症的治療和診斷藥物的研發、生產和分銷。全球人口老化和神經退化性疾病盛行率的上升是推動該市場成長的主要因素。創新重點在於緩解疾病療法、早期檢測方法和個人化醫療。監管方面的進展和合作對於加速產品開發和市場擴張至關重要。

阿茲海默症市場正經歷蓬勃發展，這主要得益於診斷技術和治療性介入的進步。治療藥物領域主導市場，其中緩解疾病藥物表現尤為強勁，反映出在延緩疾病進展方面取得了顯著進展。膽鹼酯酶抑制劑和NMDA受體拮抗劑等對症治療藥物緊隨其後，有效緩解了認知和行為症狀。診斷也是一個關鍵領域，在生物標記檢測和影像技術的推動下呈現強勁成長。生物標記相關細分領域，特別是澱粉樣蛋白和Tau蛋白檢測，成長速度最快，有助於提高早期檢測和後續觀察。包括PET和MRI掃描在內的影像技術能夠提供疾病病理的詳細資訊，是成長第二快的領域。此外，利用人工智慧和機器學習進行預測分析和個人化醫療的數位健康解決方案也正在成為一個極具潛力的細分領域。遠端醫療和遠距監測工具的整合也正在加速發展，有助於實現對患者的持續管理和互動。總而言之，這些進步為阿茲海默症市場的相關人員帶來了盈利的機會。

市場區隔
類型 早發性阿茲海默症、老年阿茲海默症、遺傳性阿茲海默症
產品 膽鹼酯酶抑制劑、NMDA受體拮抗劑、複方藥物、神經保護劑、生物製藥
服務 住院治療、門診治療、家庭醫療保健服務、諮詢服務、復健服務
科技 生物標記技術、診斷影像技術、基因組技術、數位健康技術、穿戴式技術
適用的 診斷、治療、監測和監視
最終用戶 醫院、診所、研究機構、居家醫療機構、學術機構
裝置 診斷、監測、治療和輔助設備
實施表格 基於雲端、本地部署和混合的解決方案
步 臨床前期、輕度認知障礙期、輕度老年失智症失智症期、中度老年失智症失智症期、重度老年失智症失智症期

市場概況：

阿茲海默症市場的特點是市場佔有率分佈、定價策略和新產品上市都呈現動態變化。大型製藥公司正透過新型療法和診斷工具推動創新。由於專利到期和非專利處方藥的上市，價格競爭仍然激烈。市場正經歷以疾病修正治療和早期診斷解決方案為重點的新產品上市熱潮。這種競爭環境促進了快速發展和策略聯盟的形成。從競爭標竿分析的角度來看，幾家主要企業主導著市場，而新興企業也透過創新解決方案嶄露頭角。監管的影響至關重要，嚴格的指導方針規範醫藥品認證過程。北美和歐洲處於監管發展的前沿，影響著全球市場策略。研發投入、臨床試驗結果和策略聯盟等因素塑造了競爭格局。這些因素共同構成了一個複雜的市場環境，企業在其中努力實現差異化和合規性。在技​​術進步和法規結構的推動下，阿茲海默症市場持續發展演變。

主要趨勢和促進因素：

阿茲海默症市場正經歷著由多個關鍵趨勢和促進因素帶來的動態變化。首先，全球人口老化是關鍵促進因素。隨著阿茲海默症老齡化增加而增加，這一人口趨勢導致患者群體不斷擴大，從而推動了市場需求。生物技術和基因組學的進步正在加速新型治療方法的研發。精準醫療和個人化治療日益受到關注，有望帶來更有效的干涉措施。此外，製藥公司不斷增加的研發投入正在刺激創新並推動市場成長。公眾意識和教育宣傳活動也發揮關鍵作用。提高公眾意識有助於早期診斷和干涉，這對於控制疾病進展至關重要。政府和非營利組織對教育宣傳活動的投入進一步推動了市場成長。此外，人工智慧診斷和遠端監測等數位健康技術的整合正在革新患者管理。這些技術為早期發現和持續護理提供了新的機遇，從而推動了市場的強勁擴張。

限制與挑戰：

阿茲海默症市場面臨許多重大限制和挑戰。其中一項主要挑戰是藥物研發高成本，阻礙了中小企業進入市場，從而限制了市場競爭和創新。此外，阿茲海默症病理的複雜性使得有效治療方法的研發面臨重重挑戰，導致臨床試驗失敗率居高不下。同時，嚴格的監管障礙和核准流程也延緩了新療法的上市。缺乏明確的診斷工具進一步加劇了治療難度，早期檢測仍然面臨挑戰，阻礙了及時干預，降低了治療效果。此外，社會對阿茲海默症的認知和歧視也會阻礙早期診斷和治療，這不僅影響患者的預後，也限制了市場成長。最後，高成本給患者和醫療系統帶來了沉重的經濟負擔，限制了治療的可近性和可負擔性。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 早發性阿茲海默症
    • 晚發性阿茲海默症
    • 遺傳性阿茲海默症
  • 市場規模及預測：依產品分類
    • 膽鹼酯酶抑制劑
    • NMDA受體拮抗劑
    • 複方藥物
    • 神經保護劑
    • 生物製藥
  • 市場規模及預測：依服務分類
    • 住院治療
    • 門診治療
    • 家庭醫療保健服務
    • 諮詢服務
    • 復健服務
  • 市場規模及預測：依技術分類
    • 生物標記技術
    • 診斷影像技術
    • 基因組分析技術
    • 數位健康技術
    • 穿戴式科技
  • 市場規模及預測：依應用領域分類
    • 診斷
    • 治療
    • 監測
    • 調查
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 居家醫療環境
    • 學術機構
  • 市場規模及預測：依設備分類
    • 診斷設備
    • 監測設備
    • 治療設備
    • 輔助器具
  • 市場規模及預測：依發展狀況
    • 基於雲端的解決方案
    • 本地部署解決方案
    • 混合解決方案
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • 輕度認知障礙階段
    • 輕度老年失智症失智症階段
    • 中度老年失智症失智症階段
    • 重度老年失智症失智症階段

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • AC Immune
  • BioArctic
  • Cassava Sciences
  • Anavex Life Sciences
  • Axovant Gene Therapies
  • Alzheon
  • Cortexyme
  • Annovis Bio
  • Neurotrope
  • Cognition Therapeutics
  • Intra-Cellular Therapies
  • ProMIS Neurosciences
  • Eisai Co
  • Denali Therapeutics
  • vTv Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS33609

Alzheimers Disease Marketis anticipated to expand from $3.0 billion in 2024 to $23.4 billion by 2034, growing at a CAGR of approximately 23%. The Alzheimer's Disease Market encompasses the development, production, and distribution of therapeutics and diagnostics aimed at managing and potentially curing Alzheimer's. This market is driven by an aging global population and increasing prevalence of neurodegenerative disorders. Innovations focus on disease-modifying treatments, early detection methods, and personalized medicine. Regulatory advancements and collaborations are pivotal in accelerating product development and market expansion.

The Alzheimer's Disease Market is experiencing dynamic growth, propelled by advancements in diagnostics and therapeutic interventions. The therapeutics segment dominates, with disease-modifying treatments leading performance, reflecting significant strides in slowing disease progression. Symptomatic treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, follow closely, addressing cognitive and behavioral symptoms effectively. Diagnostics, another critical segment, is witnessing robust growth, driven by biomarker-based assays and imaging technologies. Biomarkers, particularly amyloid and tau protein assays, are top-performing sub-segments, enhancing early detection and monitoring. Imaging technologies, including PET and MRI scans, are the second highest performing, offering detailed insights into disease pathology. Furthermore, digital health solutions are emerging as a promising sub-segment, leveraging AI and machine learning for predictive analytics and personalized care. The integration of telemedicine and remote monitoring tools is also gaining momentum, facilitating continuous patient management and engagement. Collectively, these advancements present lucrative opportunities for stakeholders in the Alzheimer's Disease Market.

Market Segmentation
TypeEarly-Onset Alzheimer's, Late-Onset Alzheimer's, Familial Alzheimer's
ProductCholinesterase Inhibitors, NMDA Receptor Antagonists, Combination Drugs, Neuroprotective Agents, Biologics
ServicesIn-Patient Care, Out-Patient Care, Home Healthcare Services, Counseling Services, Rehabilitation Services
TechnologyBiomarker Technology, Imaging Technology, Genomics Technology, Digital Health Technology, Wearable Technology
ApplicationDiagnosis, Treatment, Monitoring, Research
End UserHospitals, Clinics, Research Institutes, Homecare Settings, Academic Institutions
DeviceDiagnostic Devices, Monitoring Devices, Therapeutic Devices, Assistive Devices
DeploymentCloud-Based Solutions, On-Premise Solutions, Hybrid Solutions
StagePreclinical Stage, Mild Cognitive Impairment Stage, Mild Alzheimer's Dementia Stage, Moderate Alzheimer's Dementia Stage, Severe Alzheimer's Dementia Stage

Market Snapshot:

The Alzheimer's Disease market is characterized by a dynamic landscape of market share distribution, pricing strategies, and new product launches. Leading pharmaceutical companies are driving innovation with novel therapeutics and diagnostic tools. Pricing remains competitive, influenced by patent expirations and generic drug entries. The market is witnessing a surge in new product launches, focusing on disease-modifying therapies and early diagnosis solutions. This competitive environment fosters an atmosphere of rapid development and strategic partnerships. In terms of competition benchmarking, several key players dominate the market, with emerging companies gaining traction through innovative solutions. Regulatory influences play a critical role, with stringent guidelines governing drug approval processes. North America and Europe are at the forefront of regulatory advancements, impacting global market strategies. The competitive landscape is shaped by factors such as R&D investments, clinical trial outcomes, and strategic alliances. These elements contribute to a complex market environment, where companies strive to achieve differentiation and regulatory compliance. The Alzheimer's Disease market continues to evolve, driven by technological advancements and regulatory frameworks.

Geographical Overview:

The Alzheimer's Disease market is witnessing substantial growth across various regions, each with unique characteristics. North America leads with robust research initiatives and significant investments in innovative therapies. The presence of major pharmaceutical companies enhances the region's market position, fostering the development of novel treatments. Europe follows, driven by strong healthcare infrastructure and government support for Alzheimer's research. The region's focus on early diagnosis and intervention further propels market expansion. In the Asia Pacific, the market is expanding rapidly due to increasing awareness and a growing elderly population. Countries like China and Japan are emerging as key players, investing heavily in research and development. Latin America and the Middle East & Africa present new growth pockets, with rising healthcare investments and improved access to treatment options. Countries such as Brazil and the UAE are recognizing the importance of addressing Alzheimer's Disease, leading to increased market potential. These regions offer lucrative opportunities for stakeholders aiming to expand their presence in the Alzheimer's Disease market.

Key Trends and Drivers:

The Alzheimer's Disease market is experiencing dynamic shifts driven by several key trends and drivers. Firstly, the aging global population is a significant driver, as the prevalence of Alzheimer's increases with age. This demographic trend is creating an expanding patient pool, thereby boosting market demand. Advancements in biotechnology and genomics are accelerating the development of novel therapeutic approaches. Precision medicine and personalized treatments are gaining traction, offering potential for more effective interventions. Furthermore, increased investment in research and development by pharmaceutical companies is fostering innovation and driving market growth. Public awareness and advocacy efforts are also playing a crucial role. Increased awareness is leading to earlier diagnosis and intervention, which is vital for managing the disease's progression. Governments and non-profit organizations are investing in educational campaigns, further enhancing market growth. Additionally, the integration of digital health technologies, such as AI-driven diagnostics and remote monitoring, is revolutionizing patient management. These technologies offer new opportunities for early detection and continuous care, positioning the market for robust expansion.

Restraints and Challenges:

The Alzheimer's Disease market encounters several significant restraints and challenges. A primary challenge is the high cost of drug development, which impedes smaller companies from entering the market. This results in limited competition and innovation. Furthermore, the complex nature of Alzheimer's Disease pathology complicates the development of effective treatments, leading to high failure rates in clinical trials. Additionally, regulatory hurdles are substantial, with stringent approval processes delaying market entry for new therapies. The lack of definitive diagnostic tools further complicates treatment, as early detection remains elusive. This impedes timely intervention, reducing treatment efficacy. Moreover, public perception and stigma surrounding Alzheimer's Disease can deter patients from seeking early diagnosis and treatment. This not only affects patient outcomes but also limits market growth. Finally, the high cost of care and treatment poses a financial burden on patients and healthcare systems, restricting access and affordability.

Key Players:

AC Immune, BioArctic, Cassava Sciences, Anavex Life Sciences, Axovant Gene Therapies, Alzheon, Cortexyme, Annovis Bio, Neurotrope, Cognition Therapeutics, Intra-Cellular Therapies, ProMIS Neurosciences, Eisai Co, Denali Therapeutics, vTv Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Early-Onset Alzheimer's
    • 4.1.2 Late-Onset Alzheimer's
    • 4.1.3 Familial Alzheimer's
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cholinesterase Inhibitors
    • 4.2.2 NMDA Receptor Antagonists
    • 4.2.3 Combination Drugs
    • 4.2.4 Neuroprotective Agents
    • 4.2.5 Biologics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 In-Patient Care
    • 4.3.2 Out-Patient Care
    • 4.3.3 Home Healthcare Services
    • 4.3.4 Counseling Services
    • 4.3.5 Rehabilitation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biomarker Technology
    • 4.4.2 Imaging Technology
    • 4.4.3 Genomics Technology
    • 4.4.4 Digital Health Technology
    • 4.4.5 Wearable Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Diagnosis
    • 4.5.2 Treatment
    • 4.5.3 Monitoring
    • 4.5.4 Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Homecare Settings
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Diagnostic Devices
    • 4.7.2 Monitoring Devices
    • 4.7.3 Therapeutic Devices
    • 4.7.4 Assistive Devices
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud-Based Solutions
    • 4.8.2 On-Premise Solutions
    • 4.8.3 Hybrid Solutions
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical Stage
    • 4.9.2 Mild Cognitive Impairment Stage
    • 4.9.3 Mild Alzheimer's Dementia Stage
    • 4.9.4 Moderate Alzheimer's Dementia Stage
    • 4.9.5 Severe Alzheimer's Dementia Stage

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 AC Immune
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BioArctic
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cassava Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Anavex Life Sciences
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Axovant Gene Therapies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Alzheon
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cortexyme
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Annovis Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Neurotrope
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cognition Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Intra-Cellular Therapies
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 ProMIS Neurosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Eisai Co
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Denali Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 vTv Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us